101. Chagas heart disease: report on recent developments.
- Author
-
Machado FS, Jelicks LA, Kirchhoff LV, Shirani J, Nagajyothi F, Mukherjee S, Nelson R, Coyle CM, Spray DC, de Carvalho AC, Guan F, Prado CM, Lisanti MP, Weiss LM, Montgomery SP, and Tanowitz HB
- Subjects
- Animals, Defibrillators, Implantable, Disease Models, Animal, Early Diagnosis, Echocardiography, Eicosanoids physiology, Endothelin-1 biosynthesis, Endothelin-1 physiology, Heart Transplantation, Humans, Life Cycle Stages, Magnetic Resonance Angiography, Mice, Pacemaker, Artificial, Rats, Stem Cell Transplantation methods, Trypanocidal Agents therapeutic use, Trypanosoma cruzi growth & development, Vasoconstriction physiology, Chagas Cardiomyopathy diagnosis, Chagas Cardiomyopathy epidemiology, Chagas Cardiomyopathy therapy
- Abstract
Chagas disease, caused by the parasite Trypanosoma cruzi, is an important cause of cardiac disease in endemic areas of Latin America. It is now being diagnosed in nonendemic areas because of immigration. Typical cardiac manifestations of Chagas disease include dilated cardiomyopathy, congestive heart failure, arrhythmias, cardioembolism, and stroke. Clinical and laboratory-based research to define the pathology resulting from T. cruzi infection has shed light on many of the cellular and molecular mechanisms leading to these manifestations. Antiparasitic treatment may not be appropriate for patients with advanced cardiac disease. Clinical management of Chagas heart disease is similar to that used for cardiomyopathies caused by other processes. Cardiac transplantation has been successfully performed in a small number of patients with Chagas heart disease.
- Published
- 2012
- Full Text
- View/download PDF